Mental health diagnosis and medication changes after initiation of elexacaftor/tezacaftor/ivacaftor.

RATIONALE: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with varied effects on mental health (MH) in people with cystic fibrosis (PwCF). Currently published literature has focused primarily on MH diagnoses/symptoms with ETI as opposed to associated pharmacotherapy.

OBJECTIVES

We sought to evaluate the effect of ETI on MH diagnosis and associated pharmacotherapy in both adult and pediatric PwCF.

METHODS

We conducted a multicenter retrospective study in PwCF who started ETI at 7 accredited cystic fibrosis centers. Primary outcomes were the rate of MH diagnosis and medication use pre- and post-ETI initiation. Secondary outcomes were the rate of MH medication changes and dose adjustments pre- and post-ETI.

MEASUREMENTS AND MAIN

RESULTS

Overall, 1046 PwCF were included, with 453 in the "MH group" because they had either an MH diagnosis and/or MH medication use at any time point post-ETI. Mental health medication use and diagnosis both significantly increased from baseline at all time points post-ETI initiation.

CONCLUSIONS

The rate of MH medication use increased significantly from baseline at all time points in PwCF not previously prescribed MH medications, while rate of MH medication use remained consistent for those already on medications pre-ETI.